Bladder Cancer | Clinical

Clinical Benefit and Safety of Avelumab/BSC Upheld With Long-Term Data From JAVELIN Bladder 100

October 14, 2022

In an interview with Targeted Oncology, Jeanny B. Aragon-Ching, discussed recent updates from the JAVELIN Bladder 100 trial. She also discussed ongoing research involving the novel agent EV-103 in patients with advanced or metastatic urothelial cancer.